Strides Pharma Science’s board has approved the offering for subscription, on a private placement basis, up to 1,500 senior, secured, rated, unlisted, redeemable, non-convertible debentures (NCDs) of face value Rs 10 lakh each, aggregating up to Rs 150 crore. The board of directors, at its meeting, held on July 25, 2022 has considered and approved the same.
Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture o...
Strides Pharma Science gets nod to raise Rs 150 crore via NCDs
